Puma Biotechnology
In 2022, Puma entered into an exclusive license agreement with Takeda for the development and commercialization of Alisertib, an investigational aurora kinase A inhibitor.

Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to

Home About Us Pipeline News Investors Contacts Careers

Final efficacy results of neratinib in HER2-positive hormone receptor-positive early stage breast cancer from the Phase III ExteNET trial have been published in Clinical Breast Cancer. The full manuscript is available below:A Phase II trial evaluating diarrhea management strategies for NERLYNX® tablets, including dose escalation, has been published in the Annals of Oncology.  The full manuscript is available below:
Corporate Fact Sheet

RECENT NEWSEVENTSCLINICAL TRIALS


Nov. 3, 2022 - Puma Biotechnology Reports Third Quarter 2022 Financial Results
- Raises FY 2022 NERLYNX Net Product Revenue Guidance
Read

Oct. 27, 2022 - Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium
Read

Oct. 20, 2022 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
Read

Sept. 20, 2022 - Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor
Read

Sept. 11, 2022 - Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022
Read

Sept. 6, 2022 - Puma Biotechnology to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Read

Aug. 4, 2022 - Puma Biotechnology Reports Second Quarter 2022 Financial Results
Read

July 21, 2022 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
Read

June 6, 2022 - Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
Read

June 4, 2022 - Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT ‘Basket’ Trial of Neratinib at the ASCO 2022 Annual Meeting
Read

May 26, 2022 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2022 ASCO Annual Meeting
Read

May 5, 2022 - Puma Biotechnology Reports First Quarter 2022 Financial Results
Read

Apr. 27, 2022 - Puma Biotechnology Announces Publication of Neratinib Abstract Titles for the 2022 ASCO Annual Meeting
Read

Apr. 21, 2022 - Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
Read

Mar. 10, 2022 - Puma Biotechnology Announces $10 Million Private Placement
Read

Mar. 7, 2022 - Puma Biotechnology to Participate in Breast Cancer Panel at Cowen’s Annual Health Care Conference
Read

Mar. 3, 2022 - Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
Read




Upcoming Events


Dec. 6 - 10, 2022 - San Antonio Breast Cancer Symposium
More



Past Events

Nov. 3, 2022 - Puma Biotechnology 3Q-2022 Financial Results Conference Call
More

Oct. 27, 2022 - EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
More

Sept. 20, 2022 - Puma License Agreement for Alisertib
More

Sept. 12, 2022 - H.C. Wainwright 24th Annual Global Investment Conference
More

Sept. 11, 2022 - European Society for Medical Oncology (ESMO) Congress 2022
More

August 4, 2022 - Puma Biotechnology 2Q-2022 Financial Results Conference Call
More

June 3 – 7, 2022 - ASCO 2022 Annual Meeting
More

Puma-Sponsored Trials
Investigator-Sponsored Trials




Annual Report

2021 Annual Report


 Annual Report Archives


Covid-19 Pandemic

 

Contact

Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax

Medical Inquiries:
1-844-MED-PUMA (1-844-633-7862), or
medinfo@pumabiotechnology.com

Business Development:
info@pumabiotechnology.com

Investor Relations:
ir@pumabiotechnology.com

Follow Us: